SWOG Cancer Research Network shared a post on X:
“PI Krishna Soujanya Gunturu of Hartford HealthCare co-leads a reopened S2013 ICHECKIT cancer trial.
It’s developing a model to predict which patients are most likely to have serious adverse events from immune checkpoint inhibitor-based therapy.”
More posts featuring SWOG Cancer Research Network.